Clinical Study Protocol HF-301
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of NWC-401 10 mg once daily in adults with heart failure with reduced ejection fraction (HFrEF)
| Item | Detail |
|---|---|
| Protocol number | HF-301 |
| Version | 2.0 (Amendment 1), 14 February 2026 |
| Supersedes | Version 1.0, 10 June 2025 |
| Sponsor | Northwind Cardio Therapeutics |
| Contract research organization | Meridian Clinical Research |
| Investigational medicinal product | NWC-401 10 mg film-coated tablet |
| Comparator | Matching placebo tablet |
| Phase | 3 |
1. Synopsis
HF-301 is a 28-week study in approximately 400 adults with chronic, symptomatic HFrEF who remain symptomatic despite optimised guideline-directed medical therapy. Participants are randomized 1:1 to NWC-401 10 mg or matching placebo, taken orally once daily for 24 weeks, followed by a 4-week off-treatment follow-up period. The study is conducted at 8 sites in the United States, Spain, Italy and the Netherlands.
6. Schedule of activities
| Assessment | Screening | Baseline | Week 4 | Week 12 | Week 24 | Follow-up W28 |
|---|---|---|---|---|---|---|
| Visit window | Day −14 to −3 | Day 1 | Day 29 ± 3 | Day 85 ± 5 | Day 169 ± 7 | Day 197 ± 7 |
| Informed consent | X | |||||
| Eligibility review | X | X | ||||
| Randomization (IWRS) | X | |||||
| NYHA functional class | X | X | X | X | X | |
| Vital signs | X | X | X | X | X | X |
| 6-minute walk test | X | X | X | |||
| NT-proBNP (central laboratory) | X | X | X | X | ||
| Serum potassium and creatinine (central laboratory) | X | X | X | X | X | |
| Adverse event review | X | X | X | X | X | |
| Study drug dispensing and accountability | X | X | X |
Visit windows are relative to Day 1 (Baseline). Screening assessments may be spread over more than one day within the window. Central laboratory samples are taken before study drug administration.
8.4 NYHA class, vital signs and safety laboratory
The investigator assesses NYHA functional class at every visit up to Week 24. Blood pressure and heart rate are measured seated after 5 minutes of rest; body weight is measured without shoes. Serum potassium and creatinine are measured by the central laboratory at Screening, Baseline, Week 4, Week 12 and Week 24.
